EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Open Access · CC BY 4.0

Protective antibodies against enterotoxigenic Escherichia coli are generated from heat-labile toxoid vaccination and exhibit subject- and vaccine-specific diversity

Milton Maciel, Jordan C Scott, Robin L Baudier, John D Clements, Renee M Laird, Ramiro L Gutiérrez, Chad K Porter, Elizabeth B Norton

Medical Microbiology and Immunology · 2025

DOI: 10.1007/s00430-025-00817-3 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Medical Microbiology and Immunology, 2025. Verfasst von Milton Maciel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Operationally Relevant Infections Department, Naval Medical Research Command, Silver Spring, MD, USA. Hauptthemen laut MEDLINE: Enterotoxigenic Escherichia coli, Antibodies, Bacterial, Escherichia coli Vaccines, Bacterial Toxins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, PATH, Seattle WA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heat-labile toxin (LT) from enterotoxigenic Escherichia coli (ETEC) is an important pathogenic protein. Anti-LT antibodies (Abs) induced by vaccination can neutralize the toxin and potentially prevent diarrheal secretion from ~ 60% of ETEC strains expressing LT. However, only superficial investigation of the anti-toxin response is usually conducted in clinical trials. Here, we utilized human serum samples from two clinical trials performed to assess safety, immunogenicity and protection in a controlled human infection model with a LT + ST + CFA/I + H10407 ETEC strain. These Phase 1 and Phase 2b clinical trials explored a prototype ETEC adhesin (CfaE) and a chimeric adhesin-toxoid protein (dscCfaE-CTA2/LTB5) delivered intradermally or transcutaneously with a mutated form of LT (mLT) as an adjuvant. Serum samples were tested for antigen-specific IgG or IgA Abs by immunoblot, enzyme-linked immunosorbent assay (ELISA), or functional neutralizing Abs using LT holotoxin, LTA or LTB subunits. Abs to both LT subunits were present, but the response to each was altered by vaccine formulation, dose, and delivery routes as well as subject. The anti-LT IgG response correlated best to neutralizing antibodies and protection from H10407 controlled challenge when compared to other measures including serum IgA or anti-fimbriae (CfaE) Abs. In addition, our results helped to explain cohort attack rate differences in naïve unvaccinated participants and we found higher anti-LTA IgG post-challenge significantly related to ETEC severity score. Thus, strategies generating and measuring immunity to the complete AB 5 structure of LT and subunits are better determinant of assessing protective immunity against LT + or LT + ST + ETEC diarrheal secretion in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enterotoxigenic Escherichia coliAntibodies, BacterialEscherichia coli VaccinesBacterial ToxinsEscherichia coli ProteinsEnterotoxinsEscherichia coli InfectionsToxoidsHumansAntibodies, NeutralizingImmunoglobulin GFemaleImmunoglobulin AAdultMaleMiddle AgedFimbriae ProteinsYoung AdultEnzyme-Linked Immunosorbent Assay

Stichwörter der Autor:innen

AntibodiesControlled human challengeDiarrheal diseaseETECHeat-labile toxinVaccination

Substanzen

Antibodies, BacterialEscherichia coli VaccinesBacterial ToxinsEscherichia coli ProteinsEnterotoxinsheat-labile enterotoxin, E coliAntibodies, NeutralizingToxoidsImmunoglobulin GImmunoglobulin A

Autor:innen und Institutionen

  • Operationally Relevant Infections Department, Naval Medical Research Command, Silver Spring, MD, USA.
  • Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, USA.
  • Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
  • Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA, USA.
  • Biostatistics and Design Program, Oregon Health and Sciences University, Portland, USA.
  • Diarrheal Disease Research Branch, Walter Reed Army Institute of Research, Silver Spring, USA.

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • PATH, Seattle WA

Zitieren

APA

Maciel, M., Scott, J. C., Baudier, R. L., Clements, J. D., Laird, R. M., Gutiérrez, R. L., Porter, C. K., & Norton, E. B. (2025). Protective antibodies against enterotoxigenic Escherichia coli are generated from heat-labile toxoid vaccination and exhibit subject- and vaccine-specific diversity. Medical Microbiology and Immunology. https://doi.org/10.1007/s00430-025-00817-3

Vancouver

Maciel M, Scott JC, Baudier RL, Clements JD, Laird RM, Gutiérrez RL, et al. Protective antibodies against enterotoxigenic Escherichia coli are generated from heat-labile toxoid vaccination and exhibit subject- and vaccine-specific diversity. Medical Microbiology and Immunology. 2025. doi:10.1007/s00430-025-00817-3

BibTeX
@article{Maciel2025,
  author = {Maciel, Milton and Scott, Jordan C and Baudier, Robin L and Clements, John D and Laird, Renee M and Gutiérrez, Ramiro L and Porter, Chad K and Norton, Elizabeth B},
  title = {Protective antibodies against enterotoxigenic Escherichia coli are generated from heat-labile toxoid vaccination and exhibit subject- and vaccine-specific diversity},
  journal = {Medical Microbiology and Immunology},
  year = {2025},
  doi = {10.1007/s00430-025-00817-3}
}
Kostenlos starten →